Read by QxMD icon Read

Calgary depression scale schizophrenia

Xinyu Fang, Yan Chen, Yewei Wang, Chen Zhang
Patients with schizophrenia have a high risk for suicide, and therefore, identification of risk factors for suicidal ideation (SI) may be helpful to reduce suicide rate. This study aimed to detect which clinical symptoms and biochemical parameters were most strongly associated with SI. A total of 174 patients and 35 healthy controls were enrolled in our study. Patients were evaluated by the Positive and Negative Syndrome Scale (PANSS), Scale of Assessment Negative Symptoms (SANS) and the Calgary Depression Scale for Schizophrenia (CDSS) for psychiatric and depressive symptoms, and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) for cognitive function...
November 22, 2018: Psychiatry Research
David R Goldsmith, Ebrahim Haroon, Andrew H Miller, Jean Addington, Carrie Bearden, Kristin Cadenhead, Tyrone Cannon, Barbara Cornblatt, Daniel Mathalon, Thomas McGlashan, Larry Seidman, Ming Tsuang, Scott W Woods, Elaine F Walker, Diana O Perkins
Negative symptoms are common in individuals at clinical high-risk (CHR) for psychosis and are associated with worse functional outcomes. Inflammation may be one mechanism underlying negative symptoms. Inflammatory markers are altered in individuals at CHR and are associated with negative symptoms in patients with schizophrenia. We thus hypothesized that baseline inflammatory markers would predict the development of negative symptoms in individuals at CHR for psychosis. Thirty seven individuals from the North American Prodromal Longitudinal Study who met CHR criteria were included in the study...
November 26, 2018: Brain, Behavior, and Immunity
Ahmed Mhalla, Walid Bel Hadj Salah, Rim Mensi, Badii Amamou, Amal Messaoud, Leila Gassab, Wahiba Douki, Med Fadhel Najjar, Lotfi Gaha
INTRODUCTION: Cardiovascular diseases are common co morbidities of schizophrenia and constitute the main factors of high mortality in this pathology. Cardiovascular damages are favored by some risk factors, of which one of the most important is dyslipidemia. In this context, a study of lipid profile in schizophrenia is interesting.  The aims of this study were to compare the lipid profile of patients with schizophrenia to healthy controls and to investigate the associations between lipid parameters and demographics, clinical and treatment characteristics of the patients...
January 2018: La Tunisie Médicale
Rachel J Rosengard, Ashok Malla, Sally Mustafa, Srividya N Iyer, Ridha Joober, Michael Bodnar, Martin Lepage, Jai L Shah
Importance: The clinical high-risk state in psychosis is most often characterized by subthreshold psychotic symptoms (STPS) and represents a target for psychosis prevention. However, evidence suggests that between 30% and 50% of patients with a first episode of psychosis (FEP) report no prior history of STPS, indicating that not all patients with FEP experience a previous clinical high-risk phase. As with other early characteristics of illness onset, this diversity in the early course of symptoms may offer prognostic value for subsequent clinical trajectories...
October 8, 2018: JAMA Psychiatry
Yasemin Koçyiğit, Gökhan Yoca, Sevilay Karahan, Yavuz Ayhan, Mümin Kazım Yazıcı
OBJECTIVE: Current drug treatments for schizophrenia are only partially effective and combination/augmentation strategies are commonly used. Nitric Oxide (NO) may play a role in the pathophysiology of schizophrenia. L-arginine is the precursor of NO. In this study, we aimed to investigate whether L-arginine add-on to current medication might improve positive, negative, and depressive symptoms in schizophrenia/ schizoaffective disorder patients in partial remission. METHOD: The study was designed as a randomized, double-blind, placebo-controlled, crossover study of L-arginine 3 g b...
2018: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
Takeo Tominaga, Masahito Tomotake, Tomoya Takeda, Yoshinori Ueoka, Tsunehiko Tanaka, Shin-Ya Watanabe, Naomi Kameoka, Masahito Nakataki, Shusuke Numata, Yumiko Izaki, Satsuki Sumitani, Hiroko Kubo, Yasuhiro Kaneda, Tetsuro Ohmori
Purpose: The purpose of the present study was to examine clinical factors related to social function in people with schizophrenia. Patients and methods: The participants were 55 stabilized outpatients with schizophrenia. Their mean age was 39.36 (SD =10.65) years. Social function was assessed using the Quality of Life Scale (QLS). Cognitive function was evaluated with the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB)...
2018: Neuropsychiatric Disease and Treatment
Yicheng Long, Xuan Ouyang, Zhening Liu, Xudong Chen, Xinran Hu, Edwin Lee, Eric Y H Chen, Weidan Pu, Baoci Shan, Robert M Rohrbaugh
Objective: The study was aimed to investigate the possible associations among suicidal ideation, brain white matter (WM) integrity and cognitive deficit in first-episode schizophrenia (FES) using diffusion tensor imaging. Methods: The sample contained 18 FES patients with suicidal ideation (SI+), 45 FES patients without suicidal ideation (SI-) and 44 healthy controls. The Calgary Depression Scale for Schizophrenia was used to measure the suicidal ideation and depression symptoms. The whole brain WM integrity and three domains of cognitive function: working memory, verbal comprehension as well as processing speed were compared between the three groups...
2018: Frontiers in Psychiatry
Jaśmina Arabska, Anna Łucka, Dominik Strzelecki, Adam Wysokiński
AIM: Neurotrophin-3 (NT-3) is a neurotrophic factor responsible for promoting development, survival and function of neurons. NT-3 may be involved in the etiopathology of schizophrenia and mood disorders. However it must be cleared up if changes of NT-3 level are associated with schizophrenia itself or are secondary to certain symptoms (e.g. negative or depressive). The aim of this study was to examine whether the presence of negative or depressive symptoms affects peripheral NT-3 concentration in patients with schizophrenia...
September 25, 2018: Neuroscience Letters
Siv Hege Lyngstad, Erlend Strand Gardsjord, Carmen Simonsen, Magnus Johan Engen, Kristin Lie Romm, Ingrid Melle, Ann Færden
BACKGROUND: Apathy and depression are prevalent in first-episode psychosis (FEP), have overlapping clinical features and are linked to social dysfunction, with indications that persisting symptoms have an even more negative impact. Our objective was to investigate the prevalence of persisting depression (PD), persisting apathy (PA), to what extent they overlap and their relative associations to functioning during a one-year follow-up. METHODS: One hundred and twenty-five participants with a FEP were recruited, and 88 (70%) were reassessed at follow-up...
October 2018: Comprehensive Psychiatry
G Fond, M Faugere, C Faget-Agius, M Cermolacce, R Richieri, L Boyer, C Lançon
Hypovitaminosis D has been associated with, respectively, major depressive disorder, schizophrenia (SZ), and cognitive disorders in the general population, and with positive and negative symptoms and metabolic syndrome in schizophrenia. The objective was to determine the prevalence of hypovitaminosis D and associated factors in a non-selected multicentric sample of SZ subjects in day hospital. Hypovitaminosis D was defined by blood vitamin D level < 25 nM. Depressive symptoms were assessed by the Calgary Depression Rating Scale Score and Positive and Negative Syndrome Scale Score...
August 4, 2018: European Archives of Psychiatry and Clinical Neuroscience
N N Ivanets, E N Efremova
AIM: To explore psychopathological features of affective disorders in the structure of schizotypal disorder. MATERIAL AND METHODS: The study included 102 patients with schizotypal disorder, aged from 18 to 60 years. Assessment was done using clinical/ psychopathological method and psychometric scales - Calgary depression scale in patients with schizophrenia (CDSS), General Clinical Impression scale (CGI), Yang's mania scale (YMRS). RESULTS AND CONCLUSION: Affective disorders are noted in the majority of inpatients with schizotypal disorder...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Jean-Arthur Micoulaud-Franchi, Mélanie Faugere, Sebastien Weibel, Catherine Faget, Christophe Lancon, Raphaëlle Richieri, Michel Cermolacce
The severity of depressive symptoms across two discrete mental disorders should be evaluated with the same psychometrically validated tools. In patients with schizophrenia the Calgary Depression Rating Scale (CDSS) is recommended for evaluating depressive symptoms. The aim of this study was to validate the CDSS in patients with major depressive disorder. The CDSS exhibit satisfactory psychometric properties for evaluating depressive symptoms in major depressive disorder. Clinicians and researchers now have a validated scale at their disposal to evaluate depressive symptoms in various mental disorders using a transdiagnostic approach...
October 2018: Psychiatry Research
Masashi Ohta, Masahito Nakataki, Tomoya Takeda, Shusuke Numata, Takeo Tominaga, Naomi Kameoka, Hiroko Kubo, Makoto Kinoshita, Kanae Matsuura, Maki Otomo, Naoya Takeichi, Masafumi Harada, Tetsuro Ohmori
Purpose: Quality of life (QOL) is an important clinical outcome for patients with schizophrenia, and recent studies have focused on subjective QOL. We evaluated the causal relationship between psychosocial aspect of subjective QOL, symptoms, cognitive functions, and salience network (SN) dysfunction in schizophrenia using structural equation modeling (SEM). Patients and methods: We performed a cross-sectional study of 21 patients with symptomatically stabilized schizophrenia and 21 age-, sex-, and education level-matched healthy controls who underwent resting-state functional magnetic resonance imaging...
2018: Neuropsychiatric Disease and Treatment
E Kjelby, R Gjestad, I Sinkeviciute, R A Kroken, E-M Løberg, H A Jørgensen, E Johnsen
Depression is common in schizophrenia and associated with negative outcomes. Previous studies have identified heterogeneity in treatment response in schizophrenia. We aimed to investigate different trajectories of depression in patients suffering from psychosis and predictors of change in depressive symptoms during antipsychotic treatment. Two hundred and twenty-six patients >18 years acutely admitted due to psychosis were consecutively included and the follow-up was 27 weeks. The Calgary Depression Scale for Schizophrenia (CDSS) sum score was the primary outcome...
August 2018: Journal of Psychiatric Research
Zixu Yang, Keane Lim, Max Lam, Richard Keefe, Jimmy Lee
INTRODUCTION: The Positive and Negative Syndrome Scale (PANSS), a comprehensive psychopathology assessment scale used in the evaluation of psychopathology in schizophrenia, is also often used in the Ultra-High-Risk (UHR) population. This paper examined the dimensional structure of the PANSS in a UHR sample. METHODS: A total of 168 individuals assessed to be at UHR for psychosis on the Comprehensive Assessment of At-Risk Mental States (CAARMS) were evaluated on the PANSS, Calgary Depression Scale for Schizophrenia (CDSS), Beck Anxiety Inventory (BAI), Brief Assessment of Cognition in Schizophrenia (BACS), and Global Assessment of Functioning (GAF)...
May 24, 2018: Schizophrenia Research
Ahmet Tiryaki, Aykut Karahan, Filiz Civil Arslan
OBJECTIVE: The aim of this study was to investigate the relationship of the different dimensions of insight with clinical variables, symptom severity, and cognitive functions in patients with schizophrenia. METHOD: In this cross-sectional descriptive study,  66  out  patients that applied to the Karadeniz Technical University, Psychiatry Clinic and were diagnosed with schizophrenia according to DSM-IV were evaluated. The patients were evaluated with Structured Clinical Interview for DSM (SCID-I), the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale for Schizophrenia (CDSS), and the Schedule for Assessing the Three Components of Insight (SAI)...
2018: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
Sherif M Gohar, Ingrid Dieset, Nils Eiel Steen, Ragni H Mørch, Trude S Iversen, Vidar M Steen, Ole A Andreassen, Ingrid Melle
Although the relationship between positive and negative symptoms of psychosis and dyslipidemia has been thoroughly investigated in recent studies, the potential link between depression and lipid status is still under-investigated. We here examined the association between lipid levels and depressive symptomatology in patients with psychotic disorders, in addition to their possible inflammatory associations. Participants (n = 652) with the following distribution: schizophrenia, schizophreniform and schizoaffective disorder (schizophrenia group, n = 344); bipolar I, II, NOS, and psychosis NOS (non-schizophrenia group, n = 308) were recruited consecutively from the Norwegian Thematically Organized Psychosis (TOP) Study...
May 2, 2018: European Archives of Psychiatry and Clinical Neuroscience
Yan-Min Xu, Fu Li, Xiao-Bo Liu, Bao-Liang Zhong
Depression is common in patients with schizophrenia and associated with serious consequences. However, previous studies have mixed findings on characteristics of depression in schizophrenia, partly because of the use of depressive symptom scales that are not specific to schizophrenia. This study examined the prevalence and correlates of depressive symptoms in Chinese patients with schizophrenia. A consecutive sample of 349 male inpatients with schizophrenia was recruited from the largest psychiatric specialty hospital in south-central China...
June 2018: Psychiatry Research
Jie Yin Yee, Tih-Shih Lee, Jimmy Lee
Background: Identifying biomarkers to enrich prognostication and risk predictions in individuals at high risk of developing psychosis will enable stratified early intervention efforts. Brain-derived neurotrophic factor (BDNF) has been widely studied in schizophrenia and in first-episode psychosis with promising results. The aim of this study was to examine the levels of serum BDNF between healthy controls and individuals with ultra-high risk of psychosis (UHR). Methods: A sample of 106 healthy controls and 105 UHR individuals from the Longitudinal Youth at Risk Study was included in this study...
March 23, 2018: International Journal of Neuropsychopharmacology
Annemarie P M Stiekema, Anne Looijmans, Lisette van der Meer, Richard Bruggeman, Robert A Schoevers, Eva Corpeleijn, Frederike Jörg
Large studies investigating the psychosocial effects of lifestyle interventions in patients with a severe mental illness (SMI) are scarce, especially in residential patients. This large, randomized controlled, multicentre pragmatic trial assessed the psychosocial effects of a combined diet-and-exercise lifestyle intervention targeting the obesogenic environment of SMI residential patients. Twenty-nine sheltered and clinical care teams were randomized into intervention (n=15) or control (n=14) arm. Team tailored diet-and-exercise lifestyle plans were set up to change the obesogenic environment into a healthier setting, and team members were trained in supporting patients to make healthier choices...
September 2018: Schizophrenia Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"